Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435571 | 0.97 | PTGS2 (0.52) | PTGS2TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5432316 | 0.92 | MAOB (0.45) | PTGS2TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5432200 | 0.92 | MAOA (0.48) | PTGS2TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5446865 | 0.86 | MAOB (0.48) | MAOBPDE7AKMT2APIK3C2A | |
| SCHEMBL5437238 | 0.85 | PTGS2 (0.46) | PTGS2TP53CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5426673 | 0.84 | TP53 (0.54) | PTGS2TP53CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5433481 | 0.84 | MAPT (0.50) | TP53CYP1A2CYP2C9CYP2C19MAOA | |
| SCHEMBL5436106 | 0.83 | TP53 (0.51) | PTGS2TP53PDE7A | |
| SCHEMBL5435704 | 0.83 | MAOB (0.46) | TSHRMAOAMAOBPDE7AKMT2A | |
| SCHEMBL5434767 | 0.81 | ALDH1A2 (0.60) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | PTGS2 531/4885TP53 4137/4885CYP1A2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.